Myeloma Patients Europe (MPE) has launched a survey for European myeloma patients to understand their information needs.
If you are a myeloma patient who has received at least one prior treatment or is currently on their first treatment, MPE would be very grateful if you would take the time to complete the survey. The survey has been developed in collaboration with the pharmaceutical company Amgen and will be run in 12 European countries: Austria, Finland, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Sweden, Switzerland and the UK. You can find the country-specific survey link in the table below. The links for Hungary and Israel will be posted shortly.
The survey asks patients a range of questions designed to better understand myeloma patient information needs and preferences, particularly focusing on the types of information that are valued by patients to make informed treatment decisions.
The study ultimately aims to enrol 1,000 myeloma patients across Europe. The results of the survey will provide valuable insight into the needs of patients and will be used to inform the information provision strategies of a wide range of stakeholders. MPE, and its members, will also utilise the results of the survey to inform their advocacy and campaigning strategies which aim to improve the experience of patients across Europe.
If you want to share the link with somebody, please use the following: https://www.mpeurope.org/what-we-do/projects/survey-on-myeloma-patient-information-needs/
Do not copy the survey link from your internet browser. If you have a problem, please email
Where can I find further information?
For additional information or if you have any questions about the survey, please email Kate Morgan, Policy Manager, Myeloma Patients Europe at
MPE, our members and Amgen would like to thank you in advance for completing the survey.